Exosome-based drug delivery systems for the treatment of diabetes and its complications: current opinion

Extracellular vesicles and circulating nucleic acids Pub Date : 2023-01-01 DOI:10.20517/evcna.2023.32

Qi Chen, Jie Chen, Yi-Ning Liu, Su-Hua Qi, Lin-Yan Huang

{"title":"Exosome-based drug delivery systems for the treatment of diabetes and its complications: current opinion","authors":"Qi Chen, Jie Chen, Yi-Ning Liu, Su-Hua Qi, Lin-Yan Huang","doi":"10.20517/evcna.2023.32","DOIUrl":null,"url":null,"abstract":"Diabetes medication is based on controlling blood glucose and delaying the onset of related complications and is not a complete cure for diabetes. Conventional drug therapy fails to stop progressive islet β cell failure in diabetic patients. Recent studies have shown that \"exosome-based therapy\" holds great promise in treating diabetes and its complications. Exosomes are small vesicles that are stable in the bloodstream and can effectively deliver therapeutic drugs to specific tissues or organs through intercellular communication. Using exosomes as carriers for drug delivery offers several advantages. This review summarizes the benefits of exosomal drug delivery systems, drug loading methods, and their applications in treating diabetes and its complications. However, there are still challenges to overcome in using exosomal drug delivery systems, such as large-scale production, assessing the contents of exosomes, and monitoring the safety and effectiveness of the treatment in vivo. In conclusion, this review proposes the therapeutical potential of exosomes as drug carriers for developing novel drugs to provide new strategies for treating diabetes and its complications.","PeriodicalId":73008,"journal":{"name":"Extracellular vesicles and circulating nucleic acids","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Extracellular vesicles and circulating nucleic acids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/evcna.2023.32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetes medication is based on controlling blood glucose and delaying the onset of related complications and is not a complete cure for diabetes. Conventional drug therapy fails to stop progressive islet β cell failure in diabetic patients. Recent studies have shown that "exosome-based therapy" holds great promise in treating diabetes and its complications. Exosomes are small vesicles that are stable in the bloodstream and can effectively deliver therapeutic drugs to specific tissues or organs through intercellular communication. Using exosomes as carriers for drug delivery offers several advantages. This review summarizes the benefits of exosomal drug delivery systems, drug loading methods, and their applications in treating diabetes and its complications. However, there are still challenges to overcome in using exosomal drug delivery systems, such as large-scale production, assessing the contents of exosomes, and monitoring the safety and effectiveness of the treatment in vivo. In conclusion, this review proposes the therapeutical potential of exosomes as drug carriers for developing novel drugs to provide new strategies for treating diabetes and its complications.

查看原文本刊更多论文

基于外泌体的药物输送系统治疗糖尿病及其并发症:当前观点

糖尿病药物是基于控制血糖和延缓相关并发症的发生，并不能完全治愈糖尿病。常规药物治疗不能阻止糖尿病患者进行性胰岛β细胞衰竭。最近的研究表明，“以外泌体为基础的疗法”在治疗糖尿病及其并发症方面具有很大的前景。外泌体是一种在血液中稳定的小囊泡，可以通过细胞间通讯有效地将治疗药物输送到特定的组织或器官。使用外泌体作为药物递送的载体有几个优点。本文综述了外泌体给药系统、载药方法及其在治疗糖尿病及其并发症中的应用。然而，使用外泌体给药系统仍有挑战需要克服，如大规模生产，评估外泌体的含量，以及监测体内治疗的安全性和有效性。综上所述，本文综述了外泌体作为药物载体的治疗潜力，为开发新型药物提供了治疗糖尿病及其并发症的新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Extracellular vesicles and circulating nucleic acids

CiteScore

4.10

自引率

0.00%

发文量